Anti-Human CD194 (CCR4) (Mogamulizumab) - Fc Muted™

Contact us
Leinco Technologies
Product Code: LEI-LT1005
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT1005-CustomCustomEnquire
Quantity:
LEI-LT1005-500ug500 ug£408.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: KW-0761
Regulatory Status: RUO
Target Species: Human
Applications:
  • Depletion
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
CCR4 is expressed on a variety of cell types: T lymphocytes (Th2, Th17, and regulatory T cells), platelets, NK cells, monocytes, macrophages, dendritic cells, neurons, microglia, and astroglia.1 Expression of CCR4 is increased on leukemic cells in cutaneous T-cell lymphoma (CTCL).2
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Human CD194
Long Description:
Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.3 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1?infected cells and the levels of inflammatory markers related to HTLV-1?Associated Myelopathy.5
NCBI Gene:
1233
Purity:
?95% monomer by analytical SEC
Target:
CD194

References

1. Nicolay, J. et al. (2021) Eur J Immunol. 51(7):1660-1671. 2. Bogacka, J. et al. (2022) Int J Mol Sci.. 23(24):15638. 3. Yamamoto, K. et al. (2010) J Clin Oncol. 28(9):1591-8. 4. Mimura, Y. et al. (2018) Protein Cell 9(1):47-62. 5. Yamano, Y. et al. (2018) N Engl J Med 378 (6), 529-538.